whereas notably the R&D of poverty-related and neglected diseases suffers from the lack of investment from pharmaceutical companies;
ker farmacevtska podjetja zlasti premalo vlagajo v raziskave in razvoj v zvezi z boleznimi, povezanimi z revščino, in zapostavljenimi boleznimi;